Wednesday, April 10, 2024
Wednesday, April 10, 2024
HomeNewsAdvances In Parkinson's Treatment

Advances In Parkinson’s Treatment

Recent Advances In Parkinson’s Disease

New Advances Make DBS Therapy More Effective For Treating Parkinson’s Disease

Brain neurotransmitters.

Parkinsons disease is a progressive neurodegenerative disease that induces symptoms of shaking, stiffness, uncontrollable movement, poor coordination, and balance. Development of Parkinsons disease occurs at the age of 60 onward. This brain disorder develops as early as 50 years old in 5-10% of cases. Parkinsons affects nerve cells deep in the brain called basal ganglia. These cells are responsible for producing dopamine and transmitting messages for bodily functions.

Current treatments replace dopamine to the brain of a patient. Such treatments have been successful at reducing symptoms of nausea. At present, there is no cure for this brain disorder. It is important to manage Parkinsons early on, one new discovery that may help is the use of diagnostic tools.

Early detection of Parkinsons Disease

Biomarkers can be used as a diagnostic tool for identifying the stage of a disease in a patient with abnormal conditions. Researchers at Kobe and Hiroshima University developed a biomarker that detects early Parkinsons in patients’ blood serum samples such it is a quick and inexpensive process as outlined in figure 1.

Figure 1. Changes in P450 expression

Figure 2. P450 inhibition assay process

Model Analysis

Figure 3. Results of analysis using Parkinsons disease model rats and humans with Parkinsons … disease.

Multifunctional Agents With D2/d3 Receptor Agonist Antioxidant Or Iron Chelating Activities

Compared with ropinirole, D512 exhibits superior peak-dose efficacy and longer duration effects in improving the rotational activity in the 6-OHDA-induced unilaterally lesioned rat model despite having similar side effects, including drug-induced dyskinesia. In addition, D512 protects dopaminergic MN9D cells from MPP+- and 6-OHDA-induced toxicity, inhibits lipid peroxidation and caspase 3/7 activity, and rescues 6-OHDA-induced changes in nuclear morphology. Moreover, D512 protects rat adrenal pheochromocytoma PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of PD. Furthermore, D512 displays neuroprotective effects against oxidative insult produced by buthionine sulfoximine, an inhibitor of glutathione synthesis, and 6-OHDA in PC12 cells.

Latest Neuroscience Findings Include Lifestyle Factors Advances In Treatment

Parkinsons disease is a complex multi-system brain disorder impacting movement and the regulation of mood. Strides have been made in understanding the mechanism of PD and ways to prevent and slow neurodegeneration. Below is a roundup of 10 of the latest advances in understanding and treating Parkinsons that our wellness center is keeping an eye on.

You May Like: Parkinsons And Personality Changes

Read Also: Can Parkinson’s Cause Death

Updates On Currently Approved Pd Treatments

Table 1 Approved dopaminergic drugs

Later, DA receptor agonists, such as those shown in Table , were developed either as monotherapies or combination therapies with L-DOPA for the treatment of PD. Five types of DA receptors, D1D5, exist in the brain. The D1 and D5 receptors are grouped together as D1-like receptors based on their stimulatory effects on adenylyl cyclase , and the D2, D3, and D4 receptors are classified as D2-like receptors due to their inhibition of cAMP activity. Many synthetic DA agonists, including pramipexole and apomorphine, activate D2-like receptors, and have a lower incidence of motor fluctuations and dyskinesia .

Nanomedicines That Interfere With

Treatment Advances in Parkinsons Disease PsychosisTransforming the ...

Strategies that interfere with -syn expression in neurons have also received widespread attention. One remarkable approach is the targeted gene therapy proposed by Niu et al. that has provided effective repair in a PD mice model using magnetic NPs loaded with shRNA plasmid for -syn. Multifunctional magnetic NPs were effectively delivered through the blood brain barrier, prevented DA neuron degeneration as reflected by TH up-regulation and -syn down-regulation and inhibited further apoptosis in the brain. Alternatively, suppression of -syn overexpression has been demonstrated using gold NPs which could load plasmid DNA, cross the bloodbrain barrier and target specific cells. For example, the group of Y. Guan achieved successful results in carrying pDNA into the neurons, and thus inhibiting dopaminergic neuron apoptosis . These approaches have the potential to suppress -syn expression, providing a highly efficient treatment for PD.

Recommended Reading: Vascular Parkinson’s Disease Treatment

Dopaminergic Features And Their Treatment

Patients with PD usually present with features indicative of degeneration of nigrostriatal pathways. A useful clinical definition for PD is asymmetric onset of an akinetic rigid syndrome with resting tremor and a good response to levodopa. When applied by neurologists with an interest in movement disorders, this definition has a pathological correlation exceeding 98%. When treatment is considered appropriate, and this is a topic discussed in detail below, a variety of options is available. The use of dopaminergic drugs improves motor function, significantly reduces both the morbidity and mortality of PD, and improves quality of life.

Levodopa remains the drug most commonly used in PD. It is very effective in improving bradykinesia and rigidity, and in practice remains the gold standard against which other drugs are judged. Some studies, predominantly in vitro, have suggested that levodopa may be toxic. However, such data are conflicting, and some laboratory studies have suggested a growth factor-like effect for levodopa. Overall, the pre-clinical evidence for levodopa toxicity is not convincing and there are no data to indicate that any toxic action is of clinical relevance.

Table 1

Percentage of patients remaining on dopamine agonist monotherapy at years 14 and years 15 during treatment trials

New Medications For Off Time

A number of new medications approved recently are designed to reduce OFF time. These medications fall into two major categories:

  • Medications that lengthen the effect of a carbidopa/levodopa dose
  • Medications that are used as needed if medication effects wear off

Well give specific examples below. In general, new medications that extend the length of a carbidopa/levodopa dose are used if OFF time is somewhat predictable and occurs prior to next dose. New medications that are used as needed are most beneficial when OFF time is not predictable.

New medications that lengthen the effect of a dose of carbidopa/levodopa

Previous restrictions on the intake of foods containing tyramine with selective MAO-B inhibitors have been relaxed by the Food and Drug Administration . However, MAO-B inhibitors can interact with other medications, such as certain antidepressants, nasal decongestants, and narcotic pain medications. Typically, if a person is undergoing a procedure in the hospital and is taking a selective MAO-B inhibitor, they are advised to stop the medication two weeks prior to the procedure and to restart it 1-2 weeks after the procedure to avoid any unintentional medication interactions.

New formulations of levodopa designed to be used as needed if medication effects wear off

Other medications used as needed if medication effects wear off

Don’t Miss: Does Parkinson’s Disease Run In Families

Basics Of Parkinsons Disease

Parkinsons disease , or paralysis agitans, is a common neurodegenerative condition, which typically develops between the ages of 55 and 65 years. This disease was first named and described by James Parkinson in 1817. The progression of this disease is gradual and prolonged. It has a plausible familial incidence, although the estimates of these occurrences are low and usually sporadic. This disease is organized into two classifications: genetic and sporadic. Genetic PD follows Mendelian inheritance. Sporadic PD, which accounts for about 90% of all Parkinsons cases, is a more complex category in which the pathogenic mechanisms that underlie it are not yet fully understood. Nonetheless, it is known that the byzantine interactions of genetic and environmental influences play roles in the determination of sporadic PD. Several subtypes of PD exist. Each has its own set of causative factors and susceptibilities, pathology, and treatment courses. General risk factors, symptoms, and pathology will be discussed first, before addressing some of the subtypes.

Anticholinergics For Early On

VCU Health and Power Over Parkinsons: Technology Advances in Parksinsons Disease

The first pharmacological agents used in PD therapy were anticholinergic drugs. They reduce the activity of acetylcholine by acting as antagonists at choline receptors, hoping to restore the balance between dopamine and acetylcholine levels that was disturbed by PD. These drugs have largely been replaced by L-DOPA and other centrally acting dopaminergic agonists, but they still remain available for use in the treatment of PD. Benztropine, biperiden, diphenhydramine, ethopropazine, orphenadrine, procyclidine, and trihexyphenidyl are included in this therapeutic class of drugs, though there is little pharmacokinetic information available on them because of their low plasma drug concentrations. Typically, anticholinergic drugs have a greater role in tremor-predominant PD and can be a monotherapy in early stages, but are usually done in adjunct with L-DOPA or other prescribed medications.

You May Like: Just Diagnosed With Parkinson’s

Scientists From The Australian National University In Collaboration With The Florey Institute Of Neuroscience And Mental Health Have Developed A Hydrogel That Could Be Used As A One

The hydrogel is based on amino acids that can be injected into the brain when shaken it turns into a liquid, making the insertion easier, and then returns to its solid form, filling voids and thus safely transports the surrogate stem cells to the damaged parts of the brain. The real breakthrough, however, is that it is a one-time procedure. The clinical trials may begin within the next five years, after the gel proves safe for human use so far it only been tested in animals and has proven effective in combating movement disorders in Parkinsons disease in rats. Another benefit is that it is relatively cheap, and once the materials are approved for clinical use, it can be adapted for mass production and also be used to help people who have suffered from other neurological conditions such as strokes.

Parkinsons disease in Poland

It is estimated that today approximately 100,000 Poles live with Parkinsons disease, while there are over 10 million cases worldwide. There is no cure for this disease. The advanced form of the disease at various stages occurs in about 70% of cases, which is characterized primarily by the fact that it is more difficult to compensate for it with traditional pharmacological treatment. Patients then have to take higher doses of drugs more often, and sometimes such compensation is impossible, according to Dr. hab. Dariusz Koziorowski from the Department of Neurology of the Faculty of Health Sciences of the Medical University of Warsaw.

What We Know So Far

  • Weve uncovered clues to the causes and genetic involvement in Parkinsons.
  • Were figuring out the chain of events that leads to the damage and loss of brain cells.
  • Were working to advance new treatments and therapies.
  • Were exploring repurposing drugs to help manage some of the more distressing symptoms, like hallucinations and falls.
  • And we know that, although people with Parkinsons share symptoms, each persons experience of the condition and response to treatment is different.

Now, the science is ready for us to develop the new treatments and cure that people with Parkinsons so desperately need.

Research takes time. But we launched the Parkinsons Virtual Biotech to speed up the most promising potential treatments. The more we can invest, the sooner well get there.

Don’t Miss: Is Dystonia A Form Of Parkinson’s

The Shift From Research On Symptomatic Therapy To The Search For Parkinsons Disease

Based on these findings, the majority of cases with PD were assumed to present an alpha-synucleinopathy. Drug development shifted its focus from transmitters, transmitter-related receptor agonists and antagonists, and transmitter-synthesizing and -degrading enzymes to the protein chemistry, synthesis, transport, aggregation, and degradation of alpha-synuclein and other proteins related to neurodegenerative disorders, such as MAP-Tau or beta-amyloid. A now-20-year-long effort in neuroscience and drug development appears to provide the first results.

This article summarizes the recent achievements to further improve symptomatic therapy of motor PD symptoms, the still-limited attempts to provide symptomatic therapy for NMSs in PD, and the advances in the development and clinical testing of compounds, which promise to offer disease modification in already-manifest PD. However, prevention is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials, which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder , the most specific prodromal stage of PD a methodological challenge to be met in the future.

Selective D1 Receptor Agonists

Our Parkinson

Selective D1 agonists have received a resurgence of attention over the last 3 years. As derivatives of catechols, all known selective D1 agonists exert short duration effects, because they are rapidly metabolized and desensitize D1 receptors after prolonged exposure . Recently, potent noncatechol selective D1 agonists with good in vivo efficacy and promising pharmacokinetic properties were identified . PF-2334 , a G-protein-biased D1 agonist, shows sustained plasma concentrations and induces robust in vivo pharmacological responses without functional tachyphylaxis. The oral administration of PF-2334 has potent in vivo effects both on eye-blink responses in nonhuman primates and in a unilateral 6-OHDA lesioned rodent model of PD. On the other hand, 10 , a balanced agonist with highly potent effects on both signaling pathways, also displays satisfactory PK profiles, including good BBB penetrance. Importantly, 10 displays in vivo anti-Parkinsonian activity, restoring locomotion and prodyskinetic potential while potentiating behaviors indicative of dyskinesia in a 6-OHDA-lesioned mouse model of PD.

Read Also: Is Parkinson’s Disease Progressive

Rapid Eye Movement Sleep Behavior Disorder

RBD is a parasomnia effecting REM sleep characterized by the occurrence of atypical motor or cognitive events during REM sleep due to the reduction of the normal skeletal muscle atonia, thus leading to abnormal nocturnal behavior, such as punching, kicking, flailing and vocalization, self-inflicted injuries or injuries of bed partners . Up to date, RBD has been supposed to be the most common and best-characterized parasomnia in PD with an approximated prevalence between 30% and 59% . At the same time, imaging studies in RBD patients reveal a little but a quite significant symmetrical loss in striatal dopaminergic uptake. This result reflects the neuronal loss and -synuclein degeneration of the brainstem nucleus, so the brain region affected by RBD is in the second phase of the Braak hypothesis , RBD maybe precede the emergence of other symptoms of PD in the Braak disease flow chart, and it can become suggestive of preclinical PD.

Strategies For The Treatment Of Parkinsons Disease: Beyond Dopamine

  • 1Laboratorio de Neurobiología, Facultad de Ciencias de la Salud, Universidad San Sebastián, Concepción, Chile
  • 2Department of Biological Sciences, University of Limerick, Limerick, Ireland
  • 3Health Research Institute, University of Limerick, Limerick, Ireland
  • 4Department of Psychology and Neuroscience, Center for Neuroscience, University of Colorado, Boulder, CO, United States
  • 5Research & Development Service, Bay Pines VA Healthcare System, Bay Pines, FL, United States

Parkinsons disease is the second-leading cause of dementia and is characterized by a progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of intraneuronal -synuclein-positive inclusions. Therapies to date have been directed to the restoration of the dopaminergic system, and the prevention of dopaminergic neuronal cell death in the midbrain. This review discusses the physiological mechanisms involved in PD as well as new and prospective therapies for the disease. The current data suggest that prevention or early treatment of PD may be the most effective therapeutic strategy. New advances in the understanding of the underlying mechanisms of PD predict the development of more personalized and integral therapies in the years to come. Thus, the development of more reliable biomarkers at asymptomatic stages of the disease, and the use of genetic profiling of patients will surely permit a more effective treatment of PD.

Recommended Reading: When Is Parkinson’s Diagnosed

Treatment Should Be Tailored

The saying: If youve met one person with Parkinsons, youve met one person with Parkinsons reflects the fact that the condition affects people very differently. This means that treatments need to be carefully targeted to an individual. A one-size-fits-all approach to care means that people are given the same treatments regardless of their circumstance. This approach, while often applied, fails to take into account a persons experience of the disease, their unique needs and the goals they want to achieve. As a result care is often fragmented and unsatisfactory.

Being diagnosed with Parkinsons can cause understandable worry and uncertainty about the future. However, there are many effective drug treatments. Care is often supported by occupational therapists, physiotherapists and nurse specialists who can help people live fulfilling lives.

Most people with Parkinsons will be offered levodopa a drug that increases dopamine in the brain. But other drugs that help with movement problems are available, too. They are usually available in pill form or as a patch.

Until around ten years ago, treatment was often delayed until people became very disabled. Treatment is now started promptly to maintain peoples wellbeing and independence.

Science is progressing rapidly and the prompt recognition and treatment of the condition can mean that people can access an ever-increasing range of effective treatments.

Common Scale Of Motor Symptom Severity May Have Flaws: Study

Advances in Surgery for Parkinson’s Disease

A commonly used measure of how motor symptoms are affecting daily life could also for people in early stages of Parkinsons disease be taking into account the contribution of their non-motor symptoms, a study suggests. This is a likely reason for the discrepancies seen in evaluations made by patients

Also Check: What Age Parkinson’s Disease

What Will A Cure For Parkinsons Look Like

Parkinsons varies so much from person to person. There are over 40 symptoms of Parkinsons. Tremor. Pain. Hallucinations. Everyones experience is different.

Because of this, there may not be a single cure.

Instead we may need a range of different therapies to meet the needs of the individual and their specific form of the condition.

This mix may include treatments, therapies and strategies that can:

  • slow or stop the progression of the condition
  • replace or repair lost or damaged brain cells
  • control and manage particular symptoms
  • diagnose Parkinsons at the earliest possible stage.

And this could involve medical treatments, such as drugs and surgical approaches, as well as lifestyle changes, for example to diet and exercise.

Also Check: Pfnca Wellness Programs

Multifunctional Agents With D3 Receptor Agonist And Antioxidant Activities

The Dutta group also developed novel multifunctional agents with D3-preferring agonist activity along with antioxidant activity, such as the selective full D3 agonists D440 , -34 , and -9b 2019-12-1933, and the selective partial D3 agonist -8b . D440 not only exhibits in vivo efficacy in rats with 6-OHDA-induced unilateral lesions but also protects dopaminergic MN9D cells from MPP+- and 6-OHDA-induced toxicity. Both -34 and -9b significantly increase locomotor activity in an animal model of reserpine-induced PD. Moreover, -9b also exhibits strong in vivo activity in rats with 6-OHDA-induced unilateral lesions and protects MN9D cells from MPP+-induced toxicity. Of note, -8b is a selective partial D3 agonist, but it also exhibits strong in vivo activity, both in reversing akinesia in reserpine-treated rats and inducing rotation in rats with 6-OHDA-induced unilateral lesions additionally, its activity is more potent than that of -9b. However, -8b shows no neuroprotective effects against MPP+-induced toxicity in MN9D cells.

You May Like: Is Parkinson’s Hereditary Mayo Clinic


Popular Articles